These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 28277033)
21. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Czuczman MS; Porcu P; Johnson J; Niedzwiecki D; Kelly M; Hsi ED; Cook JR; Canellos G; Cheson BD; Leuk Lymphoma; 2007 Jan; 48(1):97-103. PubMed ID: 17325852 [TBL] [Abstract][Full Text] [Related]
22. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245 [TBL] [Abstract][Full Text] [Related]
23. ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients. Mebazaa A; Dupuy A; Rybojad M; Mouly F; Moulonguet I; Vignon-Pennamen MD; Rivet J; Janin A; Lebbé C; Dubertret L; Morel P; Bachelez H; Brice P Hematol J; 2005; 5(7):553-8. PubMed ID: 15692599 [TBL] [Abstract][Full Text] [Related]
24. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer. Farhat F; Kattan JG; Ghosn M Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339 [TBL] [Abstract][Full Text] [Related]
25. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851 [TBL] [Abstract][Full Text] [Related]
26. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Wollina U; Dummer R; Brockmeyer NH; Konrad H; Busch JO; Kaatz M; Knopf B; Koch HJ; Hauschild A Cancer; 2003 Sep; 98(5):993-1001. PubMed ID: 12942567 [TBL] [Abstract][Full Text] [Related]
27. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616 [TBL] [Abstract][Full Text] [Related]
29. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094 [TBL] [Abstract][Full Text] [Related]
30. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. Zackheim HS; Kashani-Sabet M; Hwang ST J Am Acad Dermatol; 1996 Apr; 34(4):626-31. PubMed ID: 8601652 [TBL] [Abstract][Full Text] [Related]
31. A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up. Bari A; Marcheselli R; Marcheselli L; Alvarez I; Pozzi S; Ferri P; Lazzaro A; Fragasso A; Neri S; Baldini L; Carella AM; Angrilli F; Guariglia R; Buda G; Stelitano C; Sacchi S; Acta Haematol; 2017; 137(1):7-14. PubMed ID: 27820922 [TBL] [Abstract][Full Text] [Related]
32. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC; J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients. Dereure O; Missan H; Girard C; Costes V; Guillot B Dermatology; 2016; 232(6):721-730. PubMed ID: 28384639 [TBL] [Abstract][Full Text] [Related]
34. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Whittaker SJ; Demierre MF; Kim EJ; Rook AH; Lerner A; Duvic M; Scarisbrick J; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Kim YH J Clin Oncol; 2010 Oct; 28(29):4485-91. PubMed ID: 20697094 [TBL] [Abstract][Full Text] [Related]
35. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. Wollina U; Graefe T; Kaatz M J Cancer Res Clin Oncol; 2001 Feb; 127(2):128-34. PubMed ID: 11216914 [TBL] [Abstract][Full Text] [Related]
36. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. Bisaccia E; Gonzalez J; Palangio M; Schwartz J; Klainer AS J Am Acad Dermatol; 2000 Aug; 43(2 Pt 1):263-71. PubMed ID: 10906649 [TBL] [Abstract][Full Text] [Related]
37. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Foss F; Duvic M; Lerner A; Waksman J; Whittaker S Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428 [TBL] [Abstract][Full Text] [Related]
38. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Kim YH; Demierre MF; Kim EJ; Lerner A; Rook AH; Duvic M; Robak T; Samtsov A; McCulloch W; Chen SC; Waksman J; Nichols J; Whittaker S Leuk Lymphoma; 2013 Feb; 54(2):284-9. PubMed ID: 22839723 [TBL] [Abstract][Full Text] [Related]
39. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611 [TBL] [Abstract][Full Text] [Related]
40. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. Garcés-Eisele SJ; Cedillo-Carvallo B; Reyes-Núñez V; Estrada-Marín L; Vázquez-Pérez R; Juárez-Calderón M; Guzmán-García MO; Dueñas-González A; Ruiz-Argüelles A J Clin Pharm Ther; 2014 Aug; 39(4):368-75. PubMed ID: 24702251 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]